NIH POLICY MANUAL

6315-1 Initiation, Review, Evaluation, and Award of Research & Development (R&D) Contracts
Issuing Offices & Phones: OA/OAMP/DAPE (301)496-6014 and OER/OEP (301)435-2690
Release Date: 10/18/2004


A. Purpose:

This chapter presents policies and procedures for the initiation, review, evaluation, negotiation, and award of NIH biomedical and behavioral Research and Development (R&D) contract projects. It applies to all contract projects for the conduct of R&D and the direct support of the conduct of R&D, including innovative testing, research, demonstration, and related efforts. The term R&D includes research, development, demonstration and R&D support. See Section H for a full definition. This chapter supplements the Health and Human Services Acquisition Regulation (HHSAR Part 315).

This chapter does not apply to contracts for purposes incidentally related to R&D, that is, non-R&D, such as:

    - The routine purchase of commercial items sold, leased, or licensed (or offered for sale, lease or license) to the general public with published price lists, etc., "off-the-shelf" laboratory or general equipment, materials, supplies, animals, or routine services for R&D projects;
    - The conduct of program evaluations, public or technical information services or clearinghouses, scientific conference or logistics support, or other services neither directly performing nor directly supporting R&D; nor
    - The performance of minor enhancements to existing equipment or systems.

This chapter is established pursuant to HHSAR Subpart 304.71 and other authority requiring the Head of the Contracting Activity to establish review and approval procedures for proposed contract actions, designate acquisition officials, and determine the criterion (or criteria) to be used in determining which contracts are to be reviewed. This chapter should not be read to abrogate any Contracting Officer authority or responsibilities as described in the Federal Acquisition Regulation (FAR), including at FAR Subpart 1.6 and FAR Subpart 15.5.

B. Background

Thorough, competent, scientific, technical and business reviews of biomedical and behavioral R&D contract projects constitute essential features of the contracting process. They serve to:

    - promote best selection of projects to accomplish high priority NIH program needs;
    - engender competition among qualified offerors;
    - establish technical ranking of proposals;
    - specify technical and business issues, for example, strengths and weaknesses, to enable meaningful discussions; and
    - promote submission of optimal Final Proposal Revisions.

All these functions help decision-making for selection of projects and sources that offer the best value to the Government. They contribute toward fulfilling identified NIH requirements for R&D contracts.

C. Policy

NIH requires competent, objective, and expeditious evaluation of biomedical and behavioral R&D contracts, conducted by qualified reviewers. Procedures implementing this policy aim to ensure optimal selection of contracts, based on established program priorities and needs, maximal opportunities for effective competition, and awards to sources most likely to achieve NIH objectives at a fair and reasonable cost. All biomedical and behavioral R&D contracts require peer review and approval of both project concepts and proposals before contract award, regardless of whether they originate from extramural or intramural program requirements.

Peer review of R&D contract concepts evaluates the basic purpose, scope, and objectives of the projects and establishes relevance, priority, and need to accomplish NIH objectives.

Peer review of R&D contract proposals provides objective evaluation of technical aspects and acceptability or unacceptability of specific proposals based on the technical evaluation criteria. Further it helps to achieve program goals by identifying the best technically qualified offerors.

The review of R&D technical proposals must be conducted in a manner consistent with the standards of quality for technical and scientific peer review (see 42 CFR 52h).

Subsequent staff reviews, including Source Selection Panels (SSP), and negotiations with offerors aim to select contractors most capable of accomplishing stated requirements to the best possible advantage to the NIH.

Responsible NIH staff must ensure that reviews provide for the most competent advice to guide decisions on selection and award of contracts. Throughout the process, staff must avoid actual or apparent conflicts of interest, maintain confidentiality of information, and comply with procurement integrity requirements.

Contract actions are subject to Protests as defined in FAR Part 33. The CO shall consider all protests and seek legal advice in conjunction with the NIH Protest Control Officer, whether protests are submitted before or after award and whether filed directly with the CO or the Government Accountability Office.

Evaluation of business proposals determines the reasonableness of cost elements and business management capabilities of offerors to perform the required work.

The Appendix shows the steps in the process from project development through contract award.

D. Responsibilities

  1. The Deputy Director for Extramural Research, NIH, establishes NIH policies and procedures for scientific review and evaluation of R&D projects, and determines the adequacy of procedures implementing those principles.

  2. The Head of the Contracting Activity, Director, Office of Acquisition Management and Policy, establishes NIH policies and procedures for business reviews, evaluations and awards for R&D contracts under requirements established in the FAR and HHSAR and determines the adequacy of procedures implementing those principles.

  3. Institute/Center (IC) Directors ensure adherence within their organizations to established NIH policies, and maintain adequate communication between program, contracting, and review staffs.

  4. Senior IC program, review, and contracting officials oversee contracting activities and are responsible for ensuring the adequacy of scientific peer review, program, and business review.

  5. Contracting Officers (COs) collaborate with Project Officers (POs) to develop Acquisition Plans/Request for Contract (AP/RFC) documents for R&D contracts based on scientific needs and market research appropriate to the circumstances. They monitor and assist technical evaluations to ensure compliance with acquisition regulations. Also, they conduct administrative/business reviews of contract proposals. COs establish the competitive range, conduct cost analyses and negotiations, select and award R&D contracts based on established requirements and results of peer reviews.

  6. POs collaborate with COs to develop AP/RFC documents and provide program information for R&D project concept and proposal reviews. They serve as a scientific resource and summarize the background and objectives of Requests for Proposals (RFPs) to ensure that the Scientific Review Group (SRG)understands the intent of the RFP. Also, they advise COs regarding technical aspects of competitive range discussions and final negotiations. See DHHS Project Officers' Contracting Handbook.

  7. Scientific Review Administrators (SRAs) establish and supervise equitable scientific reviews and evaluations for R&D contract proposals. They ensure that SRG members have no real or apparent conflicts of interest precluding their participation in proposal reviews in a given competition, unless a waiver is obtained under 42 CFR 52(h) to allow a member's participation under defined circumstances. They ensure reviewers sign and submit Conflict of Interest, Confidentiality and Non-Disclosure of Information Certifications. SRAs interact with POs and COs as necessary to understand the review requirements of the acquisition, including providing advice on evaluation criteria during AP/RFC development. They document the SRG reviews to the CO and PO. (See NIH Manual Chapter 1805, Use of Advisors in Program and Project Review and Management).

E. Procedures: Acquisition through Full and Open Competition :

  1. Presolicitation Procedures

    Presolicitation R&D contracting procedures include interactions by program, contracting, and review staffs to:

      - develop the project concept;

      - obtain scientific peer review of the concept to establish relevance, priority, and need;

      - develop the AP/RFC as a planning document; and

      - prepare a Request for Proposal (RFP), describing the Government's needs, soliciting offers based on specific requirements, often seeking innovative and original approaches to accomplish the tasks described in the RFP.

    a. Project Concept

    NIH Scientific Peer Review regulations require that ICs obtain peer review of each R&D contract project concept before issuing a Request for Proposals for biomedical and behavioral research (42 CFR 52h.10). The concept identifies the basic purpose, scope and objectives of the project.

    Timely project concept reviews are required for all R&D contract projects. Usually program staffs develop R&D project concepts based on prior discussions with advisory groups and other interactions with the scientific community. The concepts are evaluated according to IC procedures before beginning the acquisition process. If IC staff cannot easily judge whether a given contract project belongs in the R&D category, it should choose the course of peer review to ensure a broad base of expert advice and justification for contract award.

    Before issuing an RFP, the CO ensures that a peer review group/SRG (e.g. Advisory Council or Board, Board of Scientific Counselors, Program Advisory Group (PAG), Special Emphasis Panel) approved the project concept under requirements of 42 CFR 52h. Under certain circumstances, the IC Director or designee may defer or waive project concept review. See a.(2) and (3) below).

    Title 42 CFR 52h and NIH Manual Chapter 1805 restrict awarding IC staff from functioning as members or SRAs of SRGs or PAGs on contract projects or proposals for which they have other selection, award, or administration responsibilities. The PO may not serve as SRA (or PAG executive secretary) or prepare the summary minutes for R&D concept reviews.

    1. Recommendations

      PAG/SRG recommendations must address concepts for specific projects rather than broad program activities. When PAGs review project concepts, SRA or program staff must make it clear that the IC seeks their advice on the project(s) anticipated for funding as R&D contracts.

    2. Deferral from Presolicitation Concept Review

      The IC Director or designee may defer the presolicitation peer review of a project concept if he or she determines that the accomplishment of essential program objectives would otherwise be placed in jeopardy and any further delay clearly would not be in the best interest of the Government. When the Director or designee defers presolicitation concept review, he or she shall document the basis for that determination. The RFP shall state that a peer review group has not reviewed the project concept and must do so before proposal review to allow award.

      NIH prefers that different peer review groups review project concepts and proposals.

    3. Exclusions from Presolicitation Concept Review

      The IC Director or designee may determine and document to the CO that project concept review is not needed when:

        (a) the solicitation is to recompete or extend a project that is within the scope of a current project that has been peer reviewed;

        (b) Congress authorizes or mandates the IC to accomplish specific contract projects. It is considered sufficient authority to pursue those activities without additional advisory input;

        (c) projects are not for the actual conduct or direct support of R&D activities. Examples include: scientific conferences to exchange information on R&D fields or results; or purchases of commercially available supplies, services, animals; and

        (d) the solicitation is for an evaluation project that assesses productivity, impact, or quality of NIH programs, and the NIH Technical Merit Review Committee (TMRC) has already reviewed the project. Additional information on the TMRC and the use of 1% Set-Aside funds can be found at http://www1.od.nih.gov/osp/de/.

    4. Project Concept Reviews

        ICs may review project concepts by various appropriate means, including chartered program and policy advisory committees and SRGs, or seminars, conferences and workshops for specific program areas, whenever these meet the definition and composition requirements of "peer review group" in 42 CFR 52h. Also see NIH Manual Chapter 1805. Staff responsible for these reviews shall make clear to participating advisors that the IC seeks their advice with respect to the anticipated project(s). ICs may conduct concept reviews by mail or electronic means. In all cases, ICs shall present a specific concept for approval with corresponding background and rationale (estimated total costs may be included), and include the vote for approval or disapproval in formal concept review minutes.

        Concept review groups shall consider features of the purpose, scope and objectives which are specific to each R&D project, including:

          - scientific, technical, or program significance of the goals of the proposed R&D activity;

          - availability of the technology and other resources necessary to achieve the required goals;

          - extent to which identified, practical scientific or clinical uses exist for the anticipated results; and

          - adequacy of inclusion of women, minorities and children in clinical research, if applicable.

    5. Meetings

      Insofar as possible, attendance at concept review meetings may include contracting and review staff appropriate to the projects under discussion, as well as program staff responsible for program presentations and subsequent project management.

      Concept review meetings are generally open to the public under provisions of the Federal Advisory Committee Act, as amended (5 USC, Appendix 2). Persons who attend or participate in meetings, and their affiliated institutions, are eligible to receive contract awards resulting from subsequent RFPs, unless other factors contravene.

      ICs may disclose information about agency mission needs and future requirements at any time. After release of the solicitation, the CO must be the focal point of any exchange with potential offerors. When specific information about a proposed acquisition that would be necessary for the preparation of proposals is disclosed to one or more potential offerors, that information must be made available to the public as soon as practicable, but no later than the next general release of information, to avoid creating an unfair competitive advantage. See FAR 15.201(f).

    6. Documentation

      IC staff should document concept reviews with summaries of staff presentations and peer review group opinions and recommendations for approval. These summaries must become part of the official contract file.


    b. Exchanges with Industry

    NIH encourages exchanges of information among all interested parties, from the earliest identification of a requirement through receipt of proposals. Any exchange of information must be consistent with procurement integrity requirements (see FAR 3.104). An early exchange of information among industry and the program manager, contracting officer, and other participants in the acquisition process can identify and resolve concerns regarding the acquisition strategy, including:

      - proposed contract type, terms and conditions, and acquisition planning schedules;

      - the feasibility of the proposal instructions and evaluation criteria; including the approach for assessing past performance information;

      - the availability of reference documents; and

      - any other industry concerns or questions.

    Some techniques to promote early exchange of information include: industry or small business conferences; presolicitation notices; draft RFPs; site visits, etc. For additional details see FAR 15.201.


    c. Acquisition Plan/Request for Contract (AP/RFC)

    This document constitutes approval and authorization of an acquisition, allows issuance of an RFP, and future obligation of funds, according to IC procedures.

    Program staff shall initiate the preparation of the AP/RFC, which is the joint responsibility of program and contracting staff. As needed, review staff may be called upon for assistance. The AP/RFC contains all information needed to prepare the RFP. Therefore, the AP/RFC and RFP must be clear, complete, and likely to engender effective competition. In particular, the Statement of Work (or Statement of Objectives); technical evaluation criteria; and RFP Section L - Instructions, Conditions, and Notices to Offerors, must reflect those considerations.

    Whenever possible, performance-based contracting methods should be used for acquisitions including R&D. See FAR Subpart 37.6, and the Seven Steps to Performance-Based Services Acquisition.

    An AP/RFC contains documentation of clearances and a schedule of milestones for solicitation, post solicitation and award phases. See the Appendix to this document and the Acquisition Process Mapping for additional details. Information elements in the AP/RFC are detailed in FAR 7.105 and HHSAR 307.1. HHSAR 307.71 combined these requirements into a single format for use by contracting activities.

    IC components responsible for review of proposals should assist in developing technical evaluation criteria to identify ambiguities, inconsistencies or appropriateness of the criteria in relation to the statement of work.

    Final presolicitation steps include: approval of the RFC, Small Business clearance, availability notice in FedBizOpps and other selected sites; preparation and review of the RFP. After release of the solicitation, the CO must be the focal point of any exchange with potential offerors.

    The Division of Acquisition Policy and Evaluation, Office of Acquisition Management and Policy, may conduct presolicitation reviews prior to, or concurrent with, issuance of an RFP. See NIH Manual Chapter 6304.71 for more details.

    The program office's preparation of the RFC, submission to the contracting office and its approval completes the presolicitation phase of the acquisition planning process and commences the solicitation phase. The RFC is the formal document that initiates the preparation of the solicitation by the contracting office and sets the acquisition process in motion. It is the result of the planning by the PO and CO and contains much of the pertinent information necessary for the development of a sound, comprehensive solicitation.


    d. Special Considerations

    Certain projects require special clearances or approvals before the CO may execute the contract. POs and COs should consider such areas sufficiently early in the acquisition process so that they are identified as requirements in the RFP and addressed in the proposal and negotiations so that they do not delay awards. Some clearances include:

    1. Animal Welfare

      Generally, ICs will not award contracts involving the care and use of vertebrate animals until after appropriate clearance consistent with NIH Manual Chapter 6380-2/54206. These requirements apply if any animals are used in the contract, even if it is not an R&D project. See additional information at: http://grants1.nih.gov/grants/olaw/olaw.htm

    2. Biohazard Security

      To help ensure the protection of the life and health of all persons, and to help prevent damage to property, Contractors must comply with all Federal, State and local laws and regulations applicable to the contract work. The Environmental Protection Agency, Occupational Safety and Health Administration and other agencies at the Federal, State and local levels implement and/or enforce these laws.

      The CO must include HHSAR Clause 352-223.70, Safety and Health, in all awards involving toxic substances, hazardous materials, or operations.

    3. Biomedical Research Resources

      NIH designed the present policy to assist funding recipients determine:
      1) reasonable terms and conditions for making NIH-funded research resources available to scientists in other institutions in the public and private sectors (disseminating research tools), and 2) restrictions to accept as a condition of receiving access to research tools for use in NIH-funded research (acquiring research tools). The intent is to help recipients ensure the conditions they impose and accept on the transfer of research tools will facilitate further biomedical research, consistent with the requirements of the Bayh-Dole Act and NIH funding agreements. http://ott.od.nih.gov/NewPages/64FR72090.pdf

    4. Data, Data Rights, Patents, Copyrights

      Whenever contractors will use, develop or enhance data, in any form, NIH and the contractor must consider how to use, maintain, disclose, dispose, and protect it for future use. In addition to data subject to the Privacy Act, COs must carefully consider when the contractor is to develop or enhance software and other special data such as Audiovisual and Media materials. The PO and CO must explore how to license this data, and whether special permissions and copyright needs exist to protect the Government's rights to this data. The NIH Office of Technology Transfer can provide guidance in this area and should be contacted when special data needs arise in the contract requirement.

    5. Data Security

      NIH Chief Information Officer establishes data security policy in accordance with OMB Circular A-130. http://irm.cit.nih.gov/security/secplantemp.doc. The PO and IC Information Systems Security Officer must determine if the contract will be subject to the requirements of the DHHS Automated Information Systems Security Plan.

    6. Data Sharing

      NIH developed a statement on sharing research data that supports the timely release and sharing of final research data from NIH-supported studies for use by other researchers. The RFP and contract will require Offerors to include a plan for data sharing or to state why data sharing is not possible. This requirement applies to all proposals with direct costs greater than $500,000 in any single year. For more information, see the Web site below:
      http://grants1.nih.gov/grants/guide/notice-files/NOT-OD-03-032.html

    7. Electronic And Information Technology Accessibility Standards

      Section 508 of the Rehabilitation Act of 1973 applies when Federal departments or agencies develop, procure, maintain or use electronic and information technology (EIT). It requires Federal agencies to ensure their EIT allows Federal employees with disabilities to have access to, and use of, information and data comparable to the access and use by Federal employees without disabilities. Section 508 also requires members of the public with disabilities, who are seeking information or services from a Federal agency, to have access to, and use of, information and data comparable to that provided to members of the public without disabilities. See The Section 508 Standards Page, 36 CFR Part 1194 and FAR Subpart 39.2.

    8. Foreign contracts

      All foreign contracts and subcontracts require prior clearance in accordance with procedures in NIH Manual Chapter 6325-1. The need for both NIH and State Department clearances suggests that COs allow more time for such awards.

    9. Health Insurance Portability and Accountability Act (HIPAA)

      The privacy provisions of the Health Insurance Portability and Accountability Act of 1996 (HIPAA), apply to health information created or maintained by health care providers who engage in certain electronic transactions, health plans, and health care clearinghouses. Offerors need to consider the requirements for compliance. See http://dhhs.gov/ocr/hipaa.

    10. Human Subjects

      Contracts involving human subjects must meet the requirements of 45 CFR 46 and NIH Manual Chapter 6380-1. The NIH Grants Policy Statement, while mainly a grant tool, contains all of the current NIH policies concerning human subject research. Specific requirements are included in the RFP. See the NCI RFP Workform for a complete listing of possible requirements. Note that these requirements encompass many projects besides clinical trials, and it is essential to determine if specific projects fall within established requirements.

      1. Protection of Human Subjects

        See NIH Manual Chapter 6380-1, Contracts Involving Human Subjects.

      2. Inclusion of Women and Minorities in Clinical Studies.

        NIH policy is that offerors and contractors for clinical research projects include women and minorities in study populations so research findings can benefit all persons at risk of the disease, disorder, or condition under study. RFPs must identify when the policy is relevant. If the offeror does not include women/minorities in its proposed study population, or proposes a representation of women and minorities less than that anticipated by the objectives expressed in the Statement of Work, they must provide a specific rationale for this exclusion or under representation. Reviewers will evaluate this rationale during the technical peer review of proposals for its appropriateness in terms of the requirements of the solicitation. Also see: http://grants.nih.gov/grants/funding/women_min/women_min.htm

      3. Inclusion of Children Policy.

        Children (i.e. individuals under the age of 21) must be included in all human subject research unless there are scientific and ethical reasons not to include them. If offerors exclude children from research proposals, they must present an acceptable justification for the exclusion. Proposals also must include a description of the expertise of the investigative team for dealing with children at the ages included, of the appropriateness of the available facilities to accommodate the children, and the inclusion of a sufficient number of children to contribute to a meaningful analysis relative to the purpose/objective of the solicitation. For further specific requirements on inclusion of children, see the Web site below:
        http://odoerdb2.od.nih.gov/oer/policies/children.htm

      4. Data and Safety Monitoring Plan

        A plan for data and safety monitoring is required as part of the proposal for all NIH supported clinical trials. After award, the contractor must monitor on a regular basis and the conclusions of the monitoring reported to the Project Officer.

        The type of data and safety monitoring required will vary based on the type of clinical trial and the potential risks, complexity and nature of the trial. A general description of a monitoring plan establishes the overall framework for data and safety monitoring. It should describe the entity that will be responsible for the monitoring, and the policies and procedures for adverse event reporting. Multi-site clinical trials generally require the establishment of a Data Safety Monitoring Board (DSMB) based on the risk involved. The establishment of a DSMB is optional for Phase I and Phase II clinical trials.

        The DSMB/Plan is established at the time of protocol development and must be in place before the trial begins. It requires the approval of the Contractor's Institutional Review Board and the Government.

        The NIH Policy for Data and Safety Monitoring at http://grants.nih.gov/grants/guide/notice-files/not98-084.html describes examples of monitoring activities to be considered. Also see "Further Guidance on a Data and Safety Monitoring Plan for Phase I and Phase II Trials" http://grants2.nih.gov/grants/guide/notice-files/NOT-OD-00-038.html and "Guidance on Reporting Adverse Events to Institutional Review Boards for NIH-Supported Multicenter Clinical Trials" http://grants2.nih.gov/grants/guide/notice-files/not99-107.html.

      5. Human Subjects Protection Education Plan

        NIH policy requires education on the protection of human subject participants for all key personnel receiving NIH contract awards for research involving human subjects. Under this policy, key personnel include all individuals working under a contract who are responsible for the design and/or conduct of the research. For a complete description of the NIH Policy announcement on required education in the protection of human subject participants, see the NIH Guide for Grants and Contracts Announcement dated June 5, 2000 at the following Web site:
        http://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-039.html

    11. OMB Clearance/Paperwork Reduction Act

      The collection of survey or other information from ten or more respondents requires Office of Management and Budget (OMB) review and approval, consistent with NIH Manual Chapter 1825. (Also see HHSAR 307.7105.) However, when the respondents are individuals under treatment or clinical examination in connection with research on or prevention of a clinical disorder, or the interpretation of biological analyses or other specimens, or the identification or classification of those specimens, proposed projects may qualify for clinical exemption. The projects are to be submitted to the NIH Clinical Exemption Review Committee for determination of clinical exemption.
      http://www1.od.nih.gov/oma/manualchapters/management/1825/

    12. Privacy Act

      Whenever the CO determines that the Privacy Act applies to a given contract, current systems of records must be reviewed and, if necessary, a new one established and cleared in accordance with FAR Part 24 and HHSAR Part 324.

    13. Recombinant DNA

      Any contract using recombinant DNA technology requires prior clearance under provisions of "Guidelines for Research Involving Recombinant DNA Molecules". See the NIH Guide Notice at: http://grants1.nih.gov/grants/guide/notice-files/NOT-OD-02-052.html.
      The NIH Guidelines can be viewed on line at:
      http://www4.od.nih.gov/oba/rac/guidelines/guidelines.html

    14. Stem Cells

      In order to facilitate research using human embryonic stem cells, the NIH created a Human Embryonic Stem Cell Registry that lists the human embryonic stem cell lines - at varying stages of development - that meet the eligibility criteria. Only the entities that have developed stem cell lines that meet the criteria are eligible for federal funding. For further information see: http://stemcells.nih.gov/index.asp.


    e. Request for Proposals

    An RFP is the Government's official solicitation document. It communicates to prospective contractors what the Government needs to buy, and invites the submission of proposals. The purpose of the RFP is to convey all the information that prospective offerors need to prepare a proposal. The RFP includes the:

    1. Statement of Work (SOW)/Statement of Objectives (SOO)

      The RFP SOW/SOO includes specifics of the project from the AP/RFC that will enable offerors to respond in an appropriate and competitive manner to the RFP. The SOW/SOO should specify the desired results, functions, or end items without telling the offeror what has to be done to accomplish those results unless the method of performance is critical or required for the successful performance of the contract. The SOW must be clear, concise and completely define the responsibilities of the Government and the contractor. The SOO is a summary of key goals, outcomes, or both, that allows competitors to propose their solutions, including technical approach and performance standards based upon commercial business practices.

    2. Technical Proposal Instructions

      RFP Section L, Instructions, Conditions, and Notices to Offerors, informs prospective offerors that the proposal must be prepared in two parts: a technical and a business proposal, each part separate and complete in itself so evaluations of each may be performed independently of, and concurrently with, the other. RFP instructions must be tailored on a case-by-case basis to ensure appropriate consideration of the specific acquisition, for example: capability to meet recruitment goals, model protocols and prior relative experience of the named staff. Technical proposals may include proposed direct costs. Offerors' estimates of personnel, equipment, facilities and other project costs are helpful indicators of their basic understanding of the RFP requirements. ICs may set page limits for technical proposals, resumes or other parts of the proposal.

    3. Technical Evaluation Factors

      The PO must develop evaluation factors in consultation with review staff and submit them to the CO in the AP/RFC for inclusion in the RFP. Development of these factors and the assignment of the relative importance or weight to each require the exercise of judgment on a case-by-case basis because they must be tailored to the requirements of the individual acquisition. Because the factors will serve as a standard against which all proposals will be evaluated, it is imperative that staff choose them carefully to emphasize those considered to be critical in the selection of a contractor. The final evaluation factors contained in the RFP cannot be changed except by a formal amendment issued by the CO. No factors other than those set forth in the RFP may be used to evaluate proposals. The evaluation factors must be clear, concise, and fair so all potential offerors are fully aware of the bases for proposal evaluation. See HHSAR 315.204-5(c) for more details.

    4. Award Factors

      The award decision is based on evaluation factors and significant subfactors tailored to the acquisition. RFPs must clearly inform prospective offerors of the relationship and relative importance of cost or price in comparison to other evaluation factors. The factors include Technical Merit, Cost, Past Performance, Small Disadvantaged Business Participation Plans and other non-cost factors. See FAR 15.304. The relationship is expressed in one of three ways:

      All evaluation factors other than cost or price, when combined, are significantly more important than cost or price (customary for NIH R&D cost reimbursement contracts); approximately equal to cost or price; or significantly less important than cost or price.

    5. Other Considerations

      1. NIH views mandatory qualifications or special contractor standards with concern because they restrict competition. Any such restrictions should be weighed carefully, and approved as part of the AP/RFC. The RFP must provide the rationale for the restriction.
      2. RFPs allow for submission of alternate proposals, provided the offeror also submits a proposal for performance of the RFP SOW/SOO. Alternate proposals may be considered if overall performance would be improved or not compromised, and if they are in the best interest of the NIH. See FAR 15.209(a)(2).
      3. Solicitations issued under the Small Business Innovative Research (SBIR) program and as Broad Agency Announcements (BAAs) seek proposals based on broad categories or areas of interest to the Government rather than a specific SOW/SOO. Likewise, negotiation and award procedures under SBIRs and BAAs differ from "conventional" contract awards. See NIH Manual Chapters 6315-3 and 6035, respectively, for additional details.

  2. Pre-Evaluation Procedures

    1. Receipt of Proposals

      The CO must receive proposals by the RFP's published closing date and time. Proposals received after the published closing date and time are treated as Late Proposals, consistent with FAR 15.208. However, ICs that opt to include the Late Proposals and Revisions provision (HHSAR 352.215-70) in their solicitations may consider the Late Proposal under prescribed circumstances. See HHSAR 315.208.

      The CO forwards the technical proposals to program and review staff. Direct cost data are provided but not proprietary cost data such as indirect costs and fees. A transmittal memorandum should convey, at a minimum, a list of offerors and the expected receipt date of the technical evaluation report, developed in conjunction with review staff during AP/RFC preparation. The PO also receives a copy of the business proposals.

      COs are required to provide the DHHS Office of Research Integrity "ALERT System Manager" a list of principal investigator names for all research proposals received in the IC (see NIH Manual Chapter 6309-1).

      The SRA is responsible for securing and controlling distribution of all proposals provided for use in the evaluation process. After the SRG meeting, all proposals must be accounted for by returning them to the SRA, disposing of them in a manner that preserves the confidentiality of the material, or filing them in an appropriate manner.

    2. Selection/Approval of Reviewers

      Technical evaluation of biomedical and behavioral R&D contract proposals is the responsibility of review staff organizationally separate from pertinent program offices or operating divisions. SRGs must be selected in accordance with Federal Advisory Committee Act (FACA), peer review regulations, conflict of interest and procurement integrity requirements. The PO cannot serve as a member of the SRG.

      Each IC review component shall designate official(s) to supervise technical evaluations of biomedical and behavioral R&D contract proposals. These officials shall have the responsibility to develop and implement their organizations' evaluation procedures, assign SRAs to manage and conduct technical evaluation of proposals for specific acquisitions, approve SRG reviewers, designate presiding officials for SRG reviews, and develop procedures to ensure the confidentiality of materials and disposition of documents after reviews. Also, these officials ensure close communications among review, program, and contract management staffs, to promote mutual understanding of applicable policies and procedures.

      While advisers with specific expertise in pertinent scientific disciplines and disease areas perform the technical evaluation, the SRA and CO are responsible for ensuring that evaluations follow review and acquisition regulation and policy standards. POs should discuss project requirements with SRAs to ensure that required disciplines are represented on SRGs. POs also should provide SRAs with names of potential reviewers with expertise in the required scientific or technical disciplines. However, no staff may directly or indirectly solicit names of potential reviewers from a source that is preparing a response to an RFP. SRAs are responsible for deciding review group memberships and are the only staff besides the CO who may communicate with actual or potential reviewers about the evaluation.

      To ensure the integrity of the evaluation process, the SRA must remind potential reviewers that the number of proposals and identity of offerors cannot be revealed to anyone without the expressed written consent of the CO and SRA.

      Before sending materials, SRAs must determine that reviewers have no known conflicts of interest with the offerors' organizations or investigators. See 42 CFR 52h and OER Web site. SRAs will send a description of the "NIH Conflict of Interest, Confidentiality and Non-Disclosure Rules for Reviewers" and accompanying Certification Form to be signed and returned immediately by all reviewers. The reviewer must certify that he or she has no conflicts of interest (other than those identified on the form) that are likely to bias his or her evaluation and that he or she will comply with procurement integrity requirements for non-disclosure of information. Further, he or she must agree to preserve the confidentiality of the review documents and proceedings.

      If a reviewer subsequently identifies a conflict of interest, he or she should notify the SRA immediately to determine whether he or she should be disqualified as a reviewer. If no other qualified reviewer is available, the SRA may request a waiver to allow a reviewer having a conflict of interest with a particular proposal to participate in a SRG meeting and review other proposals recusing him/herself from the proposal(s) in conflict (per Class Deviation to HHSAR Subparts 315.608.73 through 315.608.78 approved April 27, 1999). Unless such a waiver is approved by the Deputy Director of Extramural Research, reviewers in conflict with one or more proposals may not participate in the peer review of the proposals in response to the same solicitation. See Delegation of Authority 1130, Program: General, No.29.

      At the completion of the review meeting, the SRG members again must sign a certification document that he or she has complied with Conflict of Interest, Confidentiality and Non-Disclosure of Information rules.

    3. Orienting/Briefing Reviewers

      IC review staff should provide appropriate review instructions and background documents to SRG members to help them understand the program and rationale for the solicitation. These materials include relevant portions of the RFP, especially the SOW/SOO, technical proposal instructions, evaluation criteria and other program information included in the RFP.

      The SRA and CO must ensure that all SRG members understand their roles and responsibilities in the competitive acquisition process, by providing written guidance emphasizing the:

        - role of peer review in the acquisition process;

        - judgment of each proposal independently based solely on the evaluation criteria reflecting the statement of work/statement of objective;

        - restriction of evaluations to the specific solicitation and contents of the written proposals;

        - evaluation and scoring of all proposals by all SRG members unless an appropriate waiver of conflict of interest has been obtained to permit recusal of specific reviewers;

        - the score should reflect and be consistent with the strengths and weaknesses identified;

        - identification of proposals' ambiguities, inconsistencies, deficiencies, and errors;

        - need for reviewers to read proposals and provide written documentation in support of their scores. Assigned reviewers will provide detailed reviews, including strengths and weaknesses with each evaluation criterion, as instructed;

        - confidentiality of review materials and SRG deliberations;

        - need to adhere to conflict of interest and procurement integrity regulations/policies;

        - protection of vertebrate animals in research; and

        - NIH policies on human subject research, as applicable.

      SRAs must caution reviewers that, as the RFP SOW/SOO already embodies prior peer-reviewed considerations of relevance, need, priority, and scientific/clinical rationale, their evaluations must not involve those factors.

      Appropriate portions of the above guidance should be reiterated by the SRA/CO at the opening of the review meeting. SRAs/COs also should briefly explain the competitive range/award process so reviewers understand how their evaluations relate to subsequent procedures.